UPDATE 1-FDA approves new dosing for Bristol-Myers Squibb's Opdivo


Bristol-Myers Squibb Co said on Tuesday the U.S. Food and Drug Administration had approved a four-week dosing schedule for its cancer drug, Opdivo. The drug belongs to a fast-growing class of drugs called PD-L1 or PD-1 inhibitors that help the immune system attack cancer by blocking a mechanism tumors use to evade detection.



from Biotech News